Rezolute, Inc.

NASDAQ:RZLT

Biotechnology

Healthcare
$4.25 +6.16%

+$0.30 today

Market cap
$411.10M
Beta
0.65
P/E (TTM)
-6.5
EPS (TTM)
-$0.78
52W Low $1.07High $11.46

Volume 2.93M

Average 2.03M

RZLT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Rezolute, Inc.NASDAQ: RZLT

Financing Cash Flow · Q3 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q3 FY2026 financing cash flow of $747K rose 7370.0% year over year, ahead of the +48.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 109.8% from the prior quarter. Over 3 fiscal years it compounded at -10.4% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +7370.0% holds above the trailing-twelve-month pace of +48.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$747K+109.8% QoQ
Last fiscal yearJun 2025
$107.33M+70.3% YoY
LTMMar 2026
$103.17M+48.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7370.0%——
1 year+70.3%——
3-year CAGR-10.4%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
107.33M USD
Year-over-year change
+70.3%
4-year CAGR
+20.1%

Financing Cash Flow vs competitors

How RZLT compares with its peers on the latest reported figures

  • RZLT's LTM Mar 2026 financing cash flow of $103.17M is the 2nd largest of the 5 companies compared; the peer median is $1.78M.
  • Its year-over-year change of +48.5% is the 2nd highest of 5, against a peer median of -40.0%.
  • Over three fiscal years its annual growth of -10.4% compares with a peer median of -1.6%.
RZLT Competitors Peer median
Financing Cash Flow for RZLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$477.84M +19.6%-1.6%71.4%
RZLTRezolute, Inc.LTM Mar 2026$103.17M +48.5%-10.4%—
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$42.35M -151.3%+13.0%34.6%
PHARPharming Group N.V.LTM Mar 2026$3.53M +109.1%—1.0%
RLYBRallybio CorporationLTM Mar 2026$19K -99.6%-93.2%2.2%
Peer median (excluding RZLT) $1.78M-40.0%-1.6%18.4%

Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(20.9M)(41.06M)(51.79M)(68.46M)(74.41M)
Depreciation & Amortization13K13K30K36K31K
Deferred Income Tax(1.78M)0(1.37M)00
Stock-Based Compensation3.97M3.69M7.27M7.36M7.12M
Change in Working Capital(2.12M)(642K)1.02M3.1M47K
Accounts Receivables00000
Inventory00000
Accounts Payables142K(11K)2.14M1.08M1.42M
Other Working Capital(2.26M)(631K)(1.12M)2.02M(1.37M)
Other Non-Cash Items384K(1.61M)352K595K(1.86M)
Operating Cash Flow(20.44M)(39.62M)(44.48M)(57.37M)(69.08M)
Capital Expenditures00(153K)00
Acquisitions (Net)00101.46M00
Purchases of Investments00(107.31M)(66.4M)(128.14M)
Sales of Investments006M115.1M113.6M
Other Investing Activities00(101.46M)00
Investing Cash Flow00(101.46M)48.7M(14.54M)
Debt Repayment15M(16.01M)000
Common Stock Issued41M122.82M12.33M49.02M107.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(4.47M)31.39M(759K)14.01M0
Financing Cash Flow51.53M148.98M11.57M63.03M107.33M
Effect of Forex Changes00000
Net Change in Cash31.09M109.36M(134.37M)54.36M23.71M
Free Cash Flow(20.44M)(39.62M)(44.63M)(57.37M)(69.08M)

Rezolute, Inc.

NASDAQ:RZLT

Intrinsic Alpha fair value

Locked

Current Price

$4.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.